March 28th 2024
Researchers shared details of a noninvasive technique that detects abnormal inflammatory cytokine profiles in the skin of asymptomatic infant patients who subsequently develop AD.
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Real-World Study Shows Dupixent Improves AD Symptoms in Children Under 12 Years
October 11th 2022A real-world study of children with moderate-to-severe atopic dermatitis (AD) in China found Dupixent can reduce symptoms and improve pruritus. Traditional therapies had little effect, according to the researchers.
The Latest Updates in Pediatric Dermatology
June 19th 2022Lisa Swanson, MD, sits down to discuss her recent presentation on pediatric dermatology featured at the 2022 SDPA Annual Summer Meeting held June 16-19, 2022, in Austin, Texas. She also describes her experience being the only pediatric dermatologist in Idaho.
Optimize Outcomes for Pediatric Patients Who Need Infusion Therapy
June 17th 2022Robert Dracker, MD, MHA, MBA, CPI discussed considerations and developmentally appropriate interventions to promote high quality, patient-centered pediatric infusion care in a presentation at the 2022 National Infusion Center Association Annual Conference.
Dupilumab's Impact on Quality of Life in Children 6 Months to 5 Years
April 11th 2022An abstract presented at the Revolutionizing Atopic Dermatitis conference discussed the impact of treatment with dupilumab on quality of life for children aged 6 months to 5 years with atopic dermatitis, as well as their caregivers.